magnitude smaller than the $1.0 billion aggregate benefit to poor kidney recipients, which is the key result of Situation 1.
If instead we had calculated the value of a deceased donor kidney separately and multiplied it by the number of deceased donor transplants, it would have significantly complicated the analysis with essentially no effect on our results. This is slightly less than our calculation of $0.052 billion in the main text, but both are more than an order of magnitude less than the $1.0 billion aggregate benefit to poor kidney recipients, the key result of Situation 1.
This simplifying assumption also conservatively allows for the possibility in Situation 2 that, with an ample supply of the superior living donor kidneys available, surgeons and patients may elect to use only living donor kidneys.
